Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
The Agentic Era: Why Biopharma Must Embrace Artificial Intelligence That Acts, Not Just Informs
2
Zitationen
1
Autoren
2025
Jahr
Abstract
Agentic artificial intelligence (AI), characterized by its capacity for autonomous task execution rather than mere assistance, heralds a fundamental paradigm shift in biopharmaceutical operations. From accelerating discovery and streamlining development to revolutionizing commercialization and governance, agentic AI systems are poised to redefine the industry's core processes. This editorial explores the burgeoning role of agentic AI as a novel operating model for biopharma, highlighting its increasing relevance across critical functions, including drug development, clinical trials, regulatory affairs, and strategic decision-making. As regulatory frameworks adapt to accommodate AI-driven methodologies, agentic systems are positioned to supersede legacy infrastructures with self-directed, adaptive engines of innovation. The future of biopharma will be defined not only by groundbreaking molecular discoveries but also by the intelligent orchestration of these advancements through autonomous machines.
Ähnliche Arbeiten
Explainable Artificial Intelligence (XAI): Concepts, taxonomies, opportunities and challenges toward responsible AI
2019 · 8.773 Zit.
Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead
2019 · 8.682 Zit.
High-performance medicine: the convergence of human and artificial intelligence
2018 · 8.242 Zit.
BioBERT: a pre-trained biomedical language representation model for biomedical text mining
2019 · 6.898 Zit.
Proceedings of the 19th International Joint Conference on Artificial Intelligence
2005 · 5.781 Zit.